10-Q · April 30, 2026
Emergent BioSolutions reported Q1 2026 earnings with total revenue of $156.1 million, decreasing by 30% compared to Q1 2025. The company achieved an EPS of $0.21, surpassing the estimated loss of $0.25, while…
EBS earnings analysis
10-Q · Filed November 2, 2026 · Our reading of the company's report
The latest report
Emergent's Q3 results were materially weaker year over year: revenue declined 52% to $110.0 million, gross margin fell to 14%, operating margin was negative 33.9%, and diluted EPS was $(0.64). Commercial and MCM…
Read full summary
Emergent's Q3 results were materially weaker year over year: revenue declined 52% to $110.0 million, gross margin fell to 14%, operating margin was negative 33.9%, and diluted EPS was $(0.64). Commercial and MCM declines were only partly offset by timing-driven Anthrax MCM growth, while NARCAN pricing, volume and competitive pressure remain significant headwinds. Nine-month operating cash flow improved to $122.4 million and debt declined to $507.7 million, but cash fell to $175.7 million and the company remains exposed to government procurement timing, restructuring execution and substantial debt obligations.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
Reported figures
- Earnings per share
- $-0.64
What stood out
-
Revenue declined 52% year over year
Q3 revenue fell to $110.0 million from $231.1 million, a 52% year-over-year decline. Product and services sales decreased 52% to $106.4 million, while contracts and grants revenue declined 60% to $3.6 million.
-
Margins and operating profit deteriorated
Gross margin fell to $15.0 million from $119.8 million, and gross margin percentage declined to 14% from 54%. Operating loss was $37.3 million versus operating income of $76.5 million in the prior-year quarter, implying an operating margin of negative 33.9%.
-
Core product categories contracted sharply
Commercial Products revenue declined 42% to $43.5 million, primarily from lower OTC NARCAN sales and unfavorable U.S. price-volume mix. MCM Products revenue fell 58% to $59.4 million, as Smallpox MCM declined 68% to $26.7 million and Other Products declined 87% to $7.6 million.
-
Anthrax growth partly offset MCM declines
Anthrax MCM revenue increased $23.7 million to $25.1 million, driven by higher USG CYFENDUS sales due to delivery timing. This partially offset the $56.9 million decline in Smallpox MCM revenue and the $49.9 million decline in Other Products revenue.
-
Quarter returned to a net loss
Diluted EPS was $(0.64), versus $0.91 in the prior-year quarter, and net loss was $32.7 million versus net income of $51.2 million. The nine-month net loss was $206.1 million, including a $191.3 million non-cash impairment charge tied to the NARCAN asset group.
-
Cash generation improved while debt fell
Nine-month operating cash flow improved to $122.4 million from $92.9 million. Capital expenditures were $7.8 million, while cash declined to $175.7 million from $205.4 million and net debt declined to $507.7 million from $572.1 million after $75.0 million of note repurchases.
What to watch
-
NARCAN competition is eroding economics
The filing adds that NARCAN faces generic competition from Teva, Padagis and Amneal and branded competition from multiple products. Commercial Products revenue fell 42% to $43.5 million, while Commercial Products gross margin percentage fell to 26% from 31%.
-
Government demand and policy timing risk
The filing adds political and social risks affecting MCM demand, including possible reduced USG purchasing and a preference for U.S.-made products. USG MCM product sales were $44.8 million in Q3 2026 versus $123.2 million in Q3 2025, while total MCM revenue fell 58% to $59.4 million.
-
Restructuring may disrupt operations
The filing adds restructuring execution risks, including operational disruption, delivery issues and potential legal claims. The August 2026 plan reduced the workforce by approximately 90 employees, incurred $9.3 million of charges, and is estimated to require total charges of approximately $10.4 million.
-
Third-party manufacturing concentration
Third-party manufacturers produce all or part of most of the Company's products, and certain manufacturers are sole sources. Any compliance failure or supply interruption could worsen results after Q3 gross margin fell to 14% and MCM gross margin fell to 19%.
-
Leverage and liquidity constraints
Liquidity remains sensitive to weak operating performance and debt service. Cash and restricted cash were $176.9 million, debt was $507.7 million, and working capital declined 18% to $436.2 million from December 31, 2025.
Management's outlook
The 10-Q provides no explicit numeric revenue or EPS guidance. Management states that liquidity, including cash and operating cash flow, is adequate to fund operations for at least the next 12 months; cash was $175.7 million and available revolver capacity was $50.0 million at September 30, 2026. The quantitative full-year outlook was provided in the November 2, 2026 earnings release rather than this filing.
Earlier filings 1
Smart money in EBS
Totals from the last full session. Insider and politician figures cover 90 days.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
See every EBS trade live.
The free pages stop at the last full session. Trader shows every trade as it prints.
Start tracking No card needed.